Nature, Published online: 18 February 2026; doi:10.1038/s41586-025-10004-2
In a phase 1 trial, personalized mRNA vaccines tailored to individual tumour mutations in triple-negative breast cancer induced robust, long-lasting T cell responses and improved prognosis.
From Nature via this RSS feed
You must log in or # to comment.